Delcath Systems to Present at Lazard Capital Markets 6th Annual Healthcare Conference

View printer-friendly version

NEW YORK, Nov. 16 -- Delcath Systems, Inc. (Nasdaq: DCTH), a medical technology company testing its proprietary treatment method for primary and metastatic cancers to the liver, today announced that its President and CEO Eamonn P. Hobbs and its CFO David A. McDonald will make a presentation to investors at the Lazard Capital Markets 6th Annual Healthcare Conference on Wednesday, November 18 at 2:45 p.m. Eastern Time at The St. Regis Hotel in New York. Mr. Hobbs and Mr. McDonald will review the company's business strategy and historic financial results.

A live webcast of the presentation will be available in the investors section of the Company's web site at The webcast also will be archived and accessible for 90 days.

Delcath Systems, Inc.

Delcath Systems, Inc. is a medical device company specializing in cancer treatment. The Company is testing a proprietary, patented drug delivery system for the treatment of liver cancers. Delcath's novel drug delivery platform is testing the delivery of ultra-high doses of anti-cancer drugs to the liver while preventing these high doses of drug from entering the patient's bloodstream. The Company is currently enrolling patients in Phase III and Phase II clinical studies for the treatment of liver cancers using high doses of melphalan. The Company maintains a broad intellectual property portfolio on a worldwide basis including the U.S., Europe, Asia and Canada. For more information, please visit the Company's website at

This Site contains information and press releases about us. This information should be considered accurate only as of the date prepared. You acknowledge that this information may change over time and you should not assume that the information is accurate at a later date. Delcath Systems, Inc. is not obligated to update the press releases and information contained in this section of the Site.